200 related articles for article (PubMed ID: 18356837)
1. Peripheral endocannabinoid system activity in patients treated with sibutramine.
Engeli S; Heusser K; Janke J; Gorzelniak K; Bátkai S; Pacher P; Harvey-White J; Luft FC; Jordan J
Obesity (Silver Spring); 2008 May; 16(5):1135-7. PubMed ID: 18356837
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss.
Bennetzen MF; Wellner N; Ahmed SS; Ahmed SM; Diep TA; Hansen HS; Richelsen B; Pedersen SB
Int J Obes (Lond); 2011 Nov; 35(11):1377-84. PubMed ID: 21326208
[TBL] [Abstract][Full Text] [Related]
4. Activation of the peripheral endocannabinoid system in human obesity.
Engeli S; Böhnke J; Feldpausch M; Gorzelniak K; Janke J; Bátkai S; Pacher P; Harvey-White J; Luft FC; Sharma AM; Jordan J
Diabetes; 2005 Oct; 54(10):2838-43. PubMed ID: 16186383
[TBL] [Abstract][Full Text] [Related]
5. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
[TBL] [Abstract][Full Text] [Related]
6. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
Smith IG; Goulder MA;
J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
[TBL] [Abstract][Full Text] [Related]
7. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
8. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects.
Engeli S; Lehmann AC; Kaminski J; Haas V; Janke J; Zoerner AA; Luft FC; Tsikas D; Jordan J
Obesity (Silver Spring); 2014 May; 22(5):E70-6. PubMed ID: 24616451
[TBL] [Abstract][Full Text] [Related]
9. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
10. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
Birkenfeld AL; Schroeder C; Pischon T; Tank J; Luft FC; Sharma AM; Jordan J
Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
[TBL] [Abstract][Full Text] [Related]
12. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
13. Long-term weight loss with sibutramine: a randomized controlled trial.
Wirth A; Krause J
JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
[TBL] [Abstract][Full Text] [Related]
14. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
16. Sibutramine--a review of clinical efficacy.
Lean ME
Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
Halpern A; Leite CC; Herszkowicz N; Barbato A; Costa AP
Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):98-102. PubMed ID: 12118266
[TBL] [Abstract][Full Text] [Related]
18. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Lindholm Å; Bixo M; Björn I; Wölner-Hanssen P; Eliasson M; Larsson A; Johnson O; Poromaa IS
Fertil Steril; 2008 May; 89(5):1221-1228. PubMed ID: 17603048
[TBL] [Abstract][Full Text] [Related]
19. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
Cuellar GE; Ruiz AM; Monsalve MC; Berber A
Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
[TBL] [Abstract][Full Text] [Related]
20. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects.
Di Marzo V; Verrijken A; Hakkarainen A; Petrosino S; Mertens I; Lundbom N; Piscitelli F; Westerbacka J; Soro-Paavonen A; Matias I; Van Gaal L; Taskinen MR
Eur J Endocrinol; 2009 Nov; 161(5):715-22. PubMed ID: 19745037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
